Previsão
O preço-alvo médio dos analistas é € 291,63 (+0,25%). A mediana é € 291,63 (+0,25%).
| Comprar |
9 |
| Manter |
13 |
| Vender |
0 |
Discussões na comunidade
- Was sind eure aktuellen Top-Aktien-Picks?
Wie die Überschrift schon verrät, würde mich interessieren, welche Aktien ihr aktuell spannend findet. Ziel ist es, ein paar interessante Titel zu entdecken, die ich vielleicht übersehen habe. Ich…
u user_acfe44 IV em Schnack
2 8
Notícias Ir para o feed de notícias
Penumbra: stroke system Thunderbolt reaches targets in THUNDER study
Penumbra reports that the vacuum thrombectomy system Thunderbolt met the predefined performance goal in the single-arm, multicenter THUNDER study: 87.5% successful reperfusion (mTICI 2b-3). First-pass reperfusion was achieved in 64.8%, mTICI 2c-3 in 70.4%, median time to revascularization was 20 minutes, and complete clot removal was achieved in 83% of cases. Device- or procedure-related serious adverse events occurred in 2.8%, symptomatic intracranial hemorrhage in 0.9%, and 90-day mortality was 11.7%. Thunderbolt recently received FDA approval and the CE mark. » Mais em de.investing.com
Penumbra reaches 52-week high at $328.69
Penumbra shares closed at a new 52-week high of $328.69. The medical device company has a market capitalization of $12.93 billion, a P/E ratio of 75.62 and revenue growth of 17.27% over the past 12 months. For Q4 2025 Penumbra reported revenue of $385.4 million and adjusted EBITDA of $79.1 million, both above analyst expectations, and shareholders approved a merger with Boston Scientific. Analysts differ on the stock’s valuation: InvestingPro rates it as overvalued, UBS remains at “neutral” with a $374 price target, and Evercore ISI raised its target to $360. » Mais em de.investing.com
Penumbra shareholders approve merger with Boston Scientific
Penumbra shareholders voted at a special general meeting to approve the merger agreement with Boston Scientific (28,564,786 yes votes, 85,334 no votes). The deal would make Penumbra a wholly owned subsidiary of Boston Scientific; completion remains subject to regulatory approvals (including Hart‑Scott‑Rodino, antitrust and foreign investment reviews). Penumbra reported Q4 2025 revenue of $385.4 million and adjusted EBITDA of $79.1 million, beating expectations; UBS maintained a "Neutral" rating, and Evercore ISI raised its price target. Additionally, the STORM‑PE study showed improved functional outcomes for vacuum thrombectomy versus pulmonary embolism. » Mais em de.investing.com
Penumbra reaches new all-time high at $352.30 and reports takeover offer from Boston Scientific
Penumbra shares rose to an all-time high of $352.30 after a strong price rally over the past year and a six-month gain of more than 52%. InvestingPro considers the stock overvalued versus fair value, the RSI signals overbought conditions, while the financial position is rated "OUTSTANDING." Penumbra released preliminary Q4 2025 revenue (USD 383.0–384.8 million) and full-year 2025 revenue guidance (approx. USD 1,401–1,403 million). Boston Scientific announced a takeover offer for Penumbra at USD 374 per share, prompting several research houses to cut their ratings to hold/neutral but set price targets at USD 374. » Mais em de.investing.com
Penumbra reports preliminary Q4 revenue growth of over 21%
Medical device maker Penumbra expects preliminary Q4 2025 revenues of $383.0 million to $384.8 million, an increase of about 21.4% to 22.0% year-over-year. Excluding China, growth in the quarter was about 23.2% to 23.8%. For full-year 2025 the company forecasts revenues of $1,401.3 million to $1,403.1 million (growth ~17.3%–17.5%). Preliminary gross margin for Q4 is estimated at 67.9%–68.1%; preliminary operating income for Q4 is $56.9 million–$60.4 million (operating margin 14.8%–15.7%). All figures are preliminary and unaudited; no date was given for the full filings. » Mais em de.investing.com
Dados financeiros
No último trimestre, Penumbra Inc registou receitas de € 362,1 mi e um ganho líquido de € 37,33 mi
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 362,1 mi | 19,81% |
| Ganho bruto | 247,47 mi | 20,79% |
| Ganho líquido | 37,33 mi | 4,47% |
| EBITDA | 54,81 mi | 16,63% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 11,46 bi |
Número de ações | 39,41 mi |
Máximo/mínimo de 52 semanas | € 330,28 - € 259,69 |
| Dividendos | Não |
Beta | 0,69 |
PER (PE Ratio) | 79,98 |
PEG (PEG Ratio) | -13,56 |
P/VC (PB Ratio) | 7,94 |
P/V (PS Ratio) | 8,06 |
Perfil da empresa
A Penumbra, Inc. concebe, desenvolve, fabrica e comercializa dispositivos médicos nos Estados Unidos e internacionalmente. A empresa oferece sistemas de trombectomia por aspiração e dispositivos acessórios, incluindo dispositivos de revascularização para trombectomia mecânica, como o Penumbra System, sob as marcas Penumbra RED, JET, ACE, 3D Revascularization Device e Penumbra ENGINE, bem como componentes e acessórios; sistemas de embolização neurovascular por espirais para tratar pacientes com aneurismas de vários tamanhos e outras lesões neurovasculares, sob as designações Penumbra Coil 400, POD400, PAC400 e Penumbra SMART Coil; e sistemas de acesso neurovascular concebidos para proporcionar acesso intracraniano para utilização numa série de terapias neurovasculares, sob as marcas Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC e PX SLIM. Disponibiliza também ferramentas de aspiração neurocirúrgica para a remoção de tecidos e fluidos, sob a marca Artemis Neuro Evacuation Device; sistemas de trombectomia por aspiração para aplicações vasculares, sob a marca Indigo System; e sistemas de espirais embólicas destacáveis para embolização periférica, sob as designações Ruby Coil e Ruby LP. Além disso, a empresa oferece microcateteres para a colocação de espirais destacáveis e dispositivos de oclusão, sob a marca LANTERN; e dispositivos de oclusão destacáveis, administráveis através de microcateter, concebidos principalmente para ocluir vasos periféricos, sob a marca POD (Penumbra Occlusion Device), bem como tecnologias imersivas baseadas em computador e terapêuticas imersivas para promover a saúde, a função motora e a cognição, sob a marca Real Immersive System; e um dispositivo complementar para utilização com a Ruby Coil e o POD na oclusão de vasos, sob as marcas Packing Coil e Packing Coil LP. A empresa vende os seus produtos através de organizações de vendas diretas e distribuidores. A Penumbra, Inc. foi constituída em 2004 e tem sede em Alameda, Califórnia.
| Nome | Penumbra Inc |
| CEO | Adam Elsesser |
| Sede | Alameda,
ca EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Cuidados de saúde: equipamentos e produtos |
| Entrada em bolsa | 18/09/2015 |
| Colaboradores | 4.700 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NYSE | PEN |
Frankfurt | 0P8.F |
Düsseldorf | 0P8.DU |
SIX | 0P8.SW |
München | 0P8.MU |